218 related articles for article (PubMed ID: 16533056)
1. Efficient metabolic engineering of GM3 on tumor cells by N-phenylacetyl-D-mannosamine.
Chefalo P; Pan Y; Nagy N; Guo Z; Harding CV
Biochemistry; 2006 Mar; 45(11):3733-9. PubMed ID: 16533056
[TBL] [Abstract][Full Text] [Related]
2. A novel cancer immunotherapy based on the combination of a synthetic carbohydrate-pulsed dendritic cell vaccine and glycoengineered cancer cells.
Qiu L; Li J; Yu S; Wang Q; Li Y; Hu Z; Wu Q; Guo Z; Zhang J
Oncotarget; 2015 Mar; 6(7):5195-203. PubMed ID: 25760071
[TBL] [Abstract][Full Text] [Related]
3. Efficient glycoengineering of GM3 on melanoma cell and monoclonal antibody-mediated selective killing of the glycoengineered cancer cell.
Wang Q; Zhang J; Guo Z
Bioorg Med Chem; 2007 Dec; 15(24):7561-7. PubMed ID: 17892942
[TBL] [Abstract][Full Text] [Related]
4. Combining synthetic carbohydrate vaccines with cancer cell glycoengineering for effective cancer immunotherapy.
Qiu L; Gong X; Wang Q; Li J; Hu H; Wu Q; Zhang J; Guo Z
Cancer Immunol Immunother; 2012 Nov; 61(11):2045-54. PubMed ID: 22539085
[TBL] [Abstract][Full Text] [Related]
5. Accessibility of N-acyl-D-mannosamines to N-acetyl-D-neuraminic acid aldolase.
Pan Y; Ayani T; Nadas J; Wen S; Guo Z
Carbohydr Res; 2004 Aug; 339(12):2091-100. PubMed ID: 15280054
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and immunological properties of N-modified GM3 antigens as therapeutic cancer vaccines.
Pan Y; Chefalo P; Nagy N; Harding C; Guo Z
J Med Chem; 2005 Feb; 48(3):875-83. PubMed ID: 15689172
[TBL] [Abstract][Full Text] [Related]
7. Role of cell surface GM3 ganglioside and sialic acid in the antitumor activity of a GM3-based vaccine in the murine B16 melanoma model.
Gabri MR; Ripoll GV; Alonso DF; Gómez DE
J Cancer Res Clin Oncol; 2002 Dec; 128(12):669-77. PubMed ID: 12474053
[TBL] [Abstract][Full Text] [Related]
8. A novel hydrophobized GM3 ganglioside/Neisseria meningitidis outer-membrane-protein complex vaccine induces tumor protection in B16 murine melanoma.
Alonso DF; Gabri MR; Guthmann MD; Fainboim L; Gomez DE
Int J Oncol; 1999 Jul; 15(1):59-66. PubMed ID: 10375594
[TBL] [Abstract][Full Text] [Related]
9. Improvement of the immune efficacy of carbohydrate vaccines by chemical modification on the GM3 antigen.
Zheng XJ; Yang F; Zheng M; Huo CX; Zhang Y; Ye XS
Org Biomol Chem; 2015 Jun; 13(22):6399-406. PubMed ID: 25982227
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of tumor cell vaccine after incorporating monophosphoryl lipid A (MPL) in tumor cell membranes containing tumor-associated ganglioside.
Ravindranath MH; Brazeau SM; Morton DL
Experientia; 1994 Jul; 50(7):648-53. PubMed ID: 8033972
[TBL] [Abstract][Full Text] [Related]
11. Ganglioside GM3-based anticancer vaccines: Reviewing the mechanism and current strategies.
Zhang J; Terreni M; Liu F; Sollogoub M; Zhang Y
Biomed Pharmacother; 2024 Jul; 176():116824. PubMed ID: 38820973
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and Evaluation of Protein Conjugates of GM3 Derivatives Carrying Modified Sialic Acids as Highly Immunogenic Cancer Vaccine Candidates.
Yu S; Wang Q; Zhang J; Wu Q; Guo Z
Medchemcomm; 2011 Jan; 2(6):524-530. PubMed ID: 21927709
[TBL] [Abstract][Full Text] [Related]
13. Cancer vaccines: an update with special focus on ganglioside antigens.
Bitton RJ; Guthmann MD; Gabri MR; Carnero AJ; Alonso DF; Fainboim L; Gomez DE
Oncol Rep; 2002; 9(2):267-76. PubMed ID: 11836591
[TBL] [Abstract][Full Text] [Related]
14. Improving the antigenicity of sTn antigen by modification of its sialic acid residue for development of glycoconjugate cancer vaccines.
Wu J; Guo Z
Bioconjug Chem; 2006; 17(6):1537-44. PubMed ID: 17105234
[TBL] [Abstract][Full Text] [Related]
15. A purified GM3 ganglioside conjugated vaccine induces specific, adjuvant-dependent and non-transient antitumour activity against B16 mouse melanoma in vitro and in vivo.
Carr A; Mazorra Z; Alonso DF; Mesa C; Valiente O; Gomez DE; Perez R; Fernandez LE
Melanoma Res; 2001 Jun; 11(3):219-27. PubMed ID: 11468510
[TBL] [Abstract][Full Text] [Related]
16. Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines.
Hakomori S
Adv Exp Med Biol; 2001; 491():369-402. PubMed ID: 14533809
[TBL] [Abstract][Full Text] [Related]
17. Antitumor effects of the GM3(Neu5Gc) ganglioside-specific humanized antibody 14F7hT against Cmah-transfected cancer cells.
Dorvignit D; Boligan KF; Relova-Hernández E; Clavell M; López A; Labrada M; Simon HU; López-Requena A; Mesa C; von Gunten S
Sci Rep; 2019 Jul; 9(1):9921. PubMed ID: 31289278
[TBL] [Abstract][Full Text] [Related]
18. Biosynthesis of sialylated lipooligosaccharides in Haemophilus ducreyi is dependent on exogenous sialic acid and not mannosamine. Incorporation studies using N-acylmannosamine analogues, N-glycolylneuraminic acid, and 13C-labeled N-acetylneuraminic acid.
Schilling B; Goon S; Samuels NM; Gaucher SP; Leary JA; Bertozzi CR; Gibson BW
Biochemistry; 2001 Oct; 40(42):12666-77. PubMed ID: 11601991
[TBL] [Abstract][Full Text] [Related]
19. Synthetic and immunological studies of 5'-N-phenylacetyl sTn to develop carbohydrate-based cancer vaccines and to explore the impacts of linkage between carbohydrate antigens and carrier proteins.
Wang Q; Ekanayaka SA; Wu J; Zhang J; Guo Z
Bioconjug Chem; 2008 Oct; 19(10):2060-7. PubMed ID: 18816108
[TBL] [Abstract][Full Text] [Related]
20. Recent development in carbohydrate-based cancer vaccines.
Guo Z; Wang Q
Curr Opin Chem Biol; 2009 Dec; 13(5-6):608-17. PubMed ID: 19766052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
